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Abstract Individuals with attention-deficit/hyperactivity
disorder (ADHD) show pervasive impairments across
family, peer, and school or work functioning that may
extend throughout the day. Psychostimulants are highly
effective medications for the treatment of ADHD, and the
development of long-acting stimulant formulations has
greatly expanded the treatment options for individuals with
ADHD. Strategies for the formulation of long-acting
stimulants include the combination of immediate-release
and delayed-release beads, and an osmotic-release oral
system. A recent development is the availability of the first
prodrug stimulant, lisdexamfetamine dimesylate (LDX).
LDX itself is inactive but is cleaved enzymatically, pri-
marily in the bloodstream, to release d-amphetamine
(d-AMP). Several clinical trials have demonstrated that
long-acting stimulants are effective in reducing ADHD
symptoms compared with placebo. Analog classroom and
simulated adult workplace environment studies have shown
that long-acting stimulants produce symptom reduction for
at least 12 h. Long-acting stimulants exhibit similar toler-
ability and safety profiles to short-acting equivalents.
While variations in gastric pH and motility can alter the
availability and absorption of stimulants released from
long-acting formulations, the systemic exposure to d-AMP
following LDX administration is unlikely to be affected by
gastrointestinal conditions. Long-acting formulations may
also improve adherence and lower abuse potential com-
pared with their short-acting counterparts. The develop-
ment of long-acting stimulants provides physicians with an
increased range of medication options to help tailor treat-
ment for individuals with ADHD.
Keywords Attention-deficit hyperactivity disorder 
Central nervous system stimulants  Amphetamines 
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common neurobehavioral disorder that is estimated to
affect 5–12 % of children and persists into adulthood in
more than half of cases (Biederman and Faraone 2005;
Polanczyk et al. 2007). ADHD is characterized by the core
symptoms of inattention, hyperactivity, and impulsivity
(American Psychiatric Association 2000). In addition,
individuals with ADHD exhibit functional impairments
that include poor intrafamily interactions, low academic
achievement and conduct problems in children and ado-
lescents, and increased risk of lower educational attain-
ment, behavior leading to arrests and traffic violations,
unemployment, and divorce in adults (Able et al. 2007;
Barkley et al. 2006; Biederman et al. 2006a; Kessler et al.
2006; Klassen et al. 2004; Sawyer et al. 2002).
Clinical guidelines for the treatment for ADHD gener-
ally recommend an individualized, multimodal plan which
includes pharmacotherapy, behavioral, and educational
interventions (American Academy of Pediatrics 2011;
Canadian Attention Deficit Hyperactivity Disorder
Resource Alliance (CADDRA) 2011; National Institute for
Health and Clinical Excellence 2009; Pliszka 2007). For
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many years, short-acting formulations of the psychostim-
ulants methylphenidate (MPH) and amphetamine (AMP)
were the mainstay of ADHD pharmacotherapy. However,
despite their well-documented efficacy, durations of action
in the range 3–6 h posed significant challenges and limi-
tations in their treatment for ADHD (Antshel et al. 2011).
The requirement for repeated dosing during the day may
cause embarrassment and stigma for the patient, difficulties
associated with storing scheduled drugs, especially in a
school environment, fragmented coverage, poor adherence,
and the potential for the diversion of drug for non-medical
use (Swanson 2003; Wolraich et al. 2001). In response to
these challenges, long-acting psychostimulants were
developed to relieve ADHD symptoms throughout the day
without the need for repeat dosing and to improve adherence
compared with short-acting agents (Adler and Nierenberg
2010; Christensen et al. 2010; Ramos-Quiroga et al. 2008;
Spencer et al. 2011; van den Ban et al. 2010).
The variation in the pharmacokinetic properties of the
different formulations of long-acting psychostimulant
therapies is reflected in their pharmacodynamic properties
including their onset, magnitude, and duration of symptom
relief. Treatment strategies should be based on an under-
standing of the efficacy and safety profile of each formu-
lation, paired with individual patient needs. Long-acting
psychostimulants, as well as the non-stimulant atomoxe-
tine, are recommended as first-line pharmacotherapies in
many countries for the management of ADHD in children,
adolescents, and adults (American Academy of Pediatrics
2011; Canadian Attention Deficit Hyperactivity Disorder
Resource Alliance (CADDRA) 2011; National Institute for
Health and Clinical Excellence 2009; Pliszka 2007). This
article will review the different controlled-release and
prodrug delivery systems of long-acting stimulants, and
examine the impact of these formulations on their phar-
macokinetics, efficacy, safety, and adherence.
Long-acting stimulant formulations
The long-acting psychostimulants that have been approved
for the treatment for ADHD can be categorized according
to the technology that has been utilized to extend or delay
the release of the active agent (Fig. 1) (Table 1). The first
generation of long-acting stimulants included sustained-
release formulations of MPH (MPH-SR) that utilized a
wax-matrix-based technology to deliver a single, prolonged
pulse of MPH. With a duration of action of up to 8 h, some
authors consider these preparations to be intermediate-
rather than long-acting (Dopheide 2009), and their efficacy
may be inferior to multiple-dose regimens of the immedi-
ate-release formulations (Swanson and Volkow 2009). The
flat (zero-order) drug delivery profile of MPH-SR may
account for the development of acute drug tolerance in
response to exposure to relatively high drug levels over a
prolonged period (Swanson 2003).
Several controlled-release (CR) stimulant formulations
were developed that combined a rapid onset of action with
extended coverage throughout the day. One strategy for the
biphasic delivery of stimulants is to mix beads with dif-
ferent drug release profiles. CR capsules contain beads that
incorporate MPH (MPH-CR) or d-AMP (AMP-CR) with
distinct immediate- and delayed-release profiles (Fig. 1).
CR-mixed AMP salts comprise equal proportions of four
AMP salts, d-AMP saccharate, d,l-AMP aspartate mono-
hydrate, d-AMP sulfate, and d,l-AMP sulfate. Each capsule
contains immediate-release and enteric-coated delayed-
release beads in a 1:1 ratio (Shire Canada Inc.; Tulloch
et al. 2002). Several stimulant drugs are based on combi-
nations of beads with immediate- and extended-release
profiles, but the proportions of the total dose of active
ingredient in the two phases of delivery vary.
An alternative technology designed to deliver the con-
trolled and biphasic delivery of stimulant medication is the
osmotic-release oral system methylphenidate (OROS-
MPH). OROS-MPH utilizes osmotic pressure to control the
rate of delivery of the active ingredient, racemic MPH.
Each capsule consists of a three-compartment core that is
enclosed by a semipermeable membrane that, in turn, is
surrounded by a drug overcoat (Fig. 1). After ingestion, the
drug overcoat provides immediate release of MPH (22 %
of the dose) (McBurnett and Starr 2011). Aqueous fluid
enters the osmotic pump compartment from the gastroin-
testinal tract and delivers the remaining dose at a first-order
rate from the core through a laser-drilled exit port (Janssen
Inc.; Swanson et al. 2004). A concentration gradient exists
between the two drug compartments, which also modifies
the rate of drug release. OROS-MPH has a smooth
ascending plasma concentration profile, which is thought to
minimize the development of acute tolerance and maintain
full efficacy across the day (Swanson et al. 2003).
Lisdexamfetamine dimesylate (LDX) is the first prodrug
stimulant. Rather than utilizing a mechanical or physical
mechanism to achieve a prolonged duration of action, LDX
is a prodrug in which d-AMP is covalently bound to the
amino acid lysine. LDX itself is therapeutically inactive
but, after oral administration, enzymatic hydrolysis of LDX
releases the therapeutically active moiety d-AMP (Pennick
2010). The rate of enzymatic conversion controls the rate at
which d-AMP becomes available. The resulting pharma-
cokinetic profile is dose-proportional and monophasic and
reflects the gradual conversion of LDX to d-AMP over the
post-dose period (Boellner et al. 2010). As enzymatic
hydrolysis occurs mostly in the bloodstream (Pennick
2010), the metabolic conversion of LDX to d-AMP is
unlikely to be affected by variations in gastric pH or
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gastrointestinal transit time (Ermer et al. 2010b; Haffey
et al. 2009; Krishnan and Zhang 2008). Thus, pharmaco-
kinetic studies have shown that the rate of d-AMP
absorption and metabolism is more consistent and pre-
dictable between and within individuals with LDX than
with extended-release mixed amphetamine salts (MAS-
XR) (Biederman et al. 2007a; Ermer et al. 2010a). Fur-
thermore, the rate of d-AMP delivery following adminis-
tration of LDX is reported to be unaffected by concurrent
administration of the acid-suppressing drug omeprazole,
whereas a shortened time to peak concentration of d-AMP
was observed when MAS-XR was taken with omeprazole
(Haffey et al. 2009) (Table 1).
Efficacy of long-acting stimulants
Clinical trial evidence supports the efficacy of long-acting
stimulants. Tables 2 and 3 present a summary of short-term
(B13-weeks), randomized, controlled clinical efficacy tri-
als of long-acting psychostimulants. The control of symp-
toms throughout the day and into the early evening is likely
to be an important factor in the overall efficacy of ADHD
pharmacotherapies (Coghill et al. 2008).
Methylphenidate sustained-release
There are limited clinical trial data of MPH-SR in children
with ADHD (Table 2). In a comparison of immediate-
release MPH (MPH-IR), with MPH-SR, controlled-release
d-AMP, and pemoline in boys with ADHD, sustained-
release MPH demonstrated efficacy versus placebo in some
behavioral measures, some performance-based tasks, and
structured assessments by counselors on the Abbreviated
Conners’ Teachers Rating Scale (ACTRS), but not on the
teacher-rated ACTRS (Pelham et al. 1990). MPH-SR has a
duration of effect of approximately 8 h (Novartis Phar-
maceuticals Canada Inc.).
Methylphenidate controlled-release
MPH-CR has shown significant efficacy in reducing
ADHD symptoms (Table 2). In children with ADHD, both
MPH-CR and IR-MPH yielded similar, statistically
significant reductions from baseline in Conners’ Parent
Rating Scale-Revised scores (CPRS-R)(Weiss et al. 2007).
However, superior symptom reduction with IR-MPH ver-
sus MPH-CR was observed based on Conners’ Teacher
Rating Scale-Revised (CTRS-R). In adults with ADHD,
MPH-CR yielded significantly better Clinical Global
Impressions-Improvement (CGI-I) ratings versus placebo
after 2 weeks (Jain et al. 2007). Using an analog classroom
crossover protocol, Schachar et al. (2008) compared MPH-
CR and IR-MPH with placebo in children with ADHD.
Significant improvements versus placebo were seen with
MPH-CR for up to 10 h post-dosing, based on change from
baseline on Inattention/Overactivity With Aggression-
Conners’ scale (IOWA-C) overall and subscores for inat-
tention/overactivity and aggression/defiance.
Osmotic-release oral system methylphenidate
OROS-MPH has demonstrated efficacy in ADHD symptom
reduction in children, adolescents, and adults (Table 2). In
a 4-week, parallel-group, placebo-controlled study, OROS-
MPH was significantly more effective than placebo in
children with ADHD, based on endpoint scores for the
Inattention/Overactivity subscale of the IOWA Conners’
Teacher Rating Scale (Wolraich et al. 2001). In a 2-week,
parallel-group study, OROS-MPH significantly reduced
ADHD Rating Scale IV (ADHD-RS-IV) scores in adoles-
cents with ADHD compared with placebo (Wilens et al.
2006a). Similar improvements compared with placebo in
the symptoms of ADHD have been described in adults
treated with OROS-MPH (Adler et al. 2009; Biederman
et al. 2006b; Medori et al. 2008).
In a head-to-head trial, subtle variations of timing and
magnitude of symptom control were observed between
MPH-CD and OROS-MPH. Although MPH-CD showed
greater efficacy in the morning hours, OROS-MPH
exhibited longer-lasting efficacy, extending up to 12 h
following a single morning dose (Pelham et al. 2001).
Head-to-head comparisons of long-acting MPH (MPH-LA)
and OROS-MPH in children with ADHD using analog
classroom protocols over 8–12 h found that both active
treatments improved Permanent Product Measure of Per-
formance (PERMP) math test scores for the number of
problems answered correctly (PERMP-C) (Lopez et al.
2003) and Swanson, Kotkin, Agler, M-Flynn, and Pelham
Rating Scale (SKAMP)-deportment and SKAMP-Attention
scores (Silva et al. 2005). While both treatments were
generally effective and well tolerated, superiority of one
treatment over the other in such laboratory school settings
is dependent on the formulation with the highest expected
plasma MPH concentration across the post-dosing period
(Swanson et al. 2004). Placebo-controlled analog class-
room studies indicate that OROS-MPH has a duration of
Fig. 1 Delivery systems of long-acting psychostimulants used in the
treatment for ADHD. Not shown are the delivery systems of MPH-SR
and Novo-MPH ER-C. MPH-SR is an extended-release formulation
in tablet form that uses a wax-based matrix to achieve prolonged
release (Ermer et al. 2010b). The delivery mechanism of Novo-MPH
ER-C has not been published (Canadian Attention Deficit Hyperac-
tivity Disorder Resource Alliance (CADDRA)). CR controlled-
release, d-AMP d-amphetamine, LDX lisdexamfetamine dimesylate,
MAS mixed amphetamine salts, MPH methylphenidate, SR sustained-
release, XR extended-release
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action of at least 12.5 h (the last time point assessed) in
children with ADHD (Armstrong et al. 2012; Murray et al.
2011; Wigal et al. 2011).
Mixed amphetamine salts extended-release
A number of randomized controlled clinical trials have
shown that controlled-release MAS (MAS-CR) is effective
versus placebo for reducing ADHD symptoms in children,
adolescents, and adults (Table 3) (Biederman et al. 2002;
Spencer et al. 2006b; Weisler et al. 2006). An analog
classroom trial in children showed that a significant effect
of MAS-CR over placebo emerged at 1.5 h post-dosing
and was maintained for up to 12 h, based on improvements
from baseline at end point in SKAMP-D and math test
scores (McCracken et al. 2003).
Dextroamphetamine controlled-release
Studies of the efficacy of controlled-release AMP (AMP-
CR) in participants with ADHD are limited. Pelham et al.
compared treatment arms with AMP-CR, IR-MPH, MPH-
SR, and pemoline in boys. Although all treatments were
superior to placebo in some behavioral measures, only
pemoline and AMP-XR were superior to placebo by the
teacher-rated ACTRS. The duration of efficacy was char-
acterized as within 2 h of ingestion and up to 9 h post-dose
(Pelham et al. 1990). In an analog classroom trial of AMP-
CR in children, objective actometer measures and parent
ratings of behavior were improved compared with placebo
from 1.75 to 12 h following a single morning dose. The
effects of AMP-CR were ‘‘less robust’’ than those of IR-
MAS in the morning hours after dosing but were extended
for 3–6 h longer (James et al. 2001).
Lisdexamfetamine dimesylate
The efficacy of LDX compared with placebo in reducing
the symptoms of ADHD has been demonstrated in patients
across the lifespan (Table 3). In 4-week trials of LDX 30,
50, and 70 mg in children, adolescents, and adults with
ADHD, all doses of LDX demonstrated significant
improvements in ADHD-RS-IV scores compared with
placebo (Adler et al. 2008; Biederman et al. 2007b; Fin-
dling et al. 2011). Mean rates of response (defined as
[30 % improvement in ADHD-RS-IV scores and CGI-I
ratings of much improved or very much improved) were
approximately 80 % at end point in children treated with
LDX 70 mg compared with less than 20 % for placebo
(Biederman et al. 2007b). Furthermore, improvements
compared to placebo in CPRS-R scores in children with
ADHD were maintained until 6 pm following an early
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classroom study in children with ADHD, the therapeutic
effects of LDX extended from 1.5 to 13 h post-dose (the
first and last time points assessed) based on improvements
in SKAMP and PERMP scores (Wigal et al. 2009). In a
simulated adult workplace environment study, the thera-
peutic effects of LDX were maintained from 2 to 14 h post-
dose (the first and last time points measured) in adults with
ADHD, as shown by improvements in PERMP scores
versus placebo (Wigal et al. 2010). The demonstration that
the efficacy of LDX is maintained for at least 13 h in
children and 14 h in adults suggests that this prodrug may
be the longest-acting stimulant treatment for ADHD.
Meta-analyses of the effectiveness of long-acting
stimulants
Meta-analyses have compared efficacy outcomes from
multiple studies of different stimulant formulations (Fara-
one 2009, 2012; Faraone and Glatt 2010). In an analysis of
32 trials of 16 medications in youths with ADHD, the mean
effect size for long-acting stimulants was 0.95 compared
with 0.99 for immediate-release stimulants (Faraone 2009).
Similarly, in 19 trials of 13 ADHD drugs in adults, mean
effect sizes were 0.73 and 0.96 for long-acting and
immediate-release stimulants, respectively (Faraone and
Glatt 2010). A meta-analysis of efficacy studies in children
with ADHD, based only on ADHD Rating Scale and
Clinical Global Impressions outcomes, found that a pooled
effect size for LDX of approximately 1.5 was significantly
(p \ 0.001) greater than the pooled effect size of the other
medications (Faraone 2012). In adult studies, LDX effect
sizes were similar to those of other medications. Using
numbers-needed-to-treat (NNT) to compare the efficacy of
stimulants medications across 23 clinical trials in children
and adolescents, NNT (95 % confidence intervals) were
slightly lower (i.e., fewer patients were required to see a
positive effect) for formulations of AMP (2.0 [1.7, 2.2])
than MPH (2.6 [2.4, 2.8]), although mean NNT values were
not calculated for long-acting and immediate-release for-
mulations (Faraone et al. 2006).
Safety of psychostimulants
Short- and long-acting psychostimulants share similar
adverse event profiles (Banaschewski et al. 2006). Adverse
events most commonly associated with the use of psy-
chostimulants to treat ADHD include neurological (head-
ache, dizziness, insomnia, seizures), psychiatric (mood/
anxiety, tics, psychosis), and gastrointestinal (abdominal
pain, poor appetite leading to weight loss/slowed growth)
effects. In general, these events are mild and/or temporary
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of psychostimulants to treat ADHD include their effects on
growth and cardiovascular parameters, and their potential
for abuse.
Effect on weight and growth
An analysis of 20 longitudinal studies found that long-term
psychostimulant use in children with ADHD resulted in
statistically significant delays in growth versus age-related
norms (Faraone et al. 2008). Effects appeared to be dose-
related, were more apparent for weight than height, were
similar between MPH and AMP formulations, and, in many
cases, appeared to normalize over time despite continued
treatment (Faraone et al. 2008). In the MTA (Multimodal
Treatment Study of Children with ADHD), the largest
longitudinal study of children with ADHD, average relative
size of patient (a composite of height and weight as
z scores) was negatively related to the average cumulative
exposure to psychostimulants. Growth slowing for newly
medicated versus untreated participants was found for the
first 14 months, was attenuated at 24 months, and was non-
significant at 36 months (Murray et al. 2008; Swanson
et al. 2007). Nevertheless, it is recommended that height
and weight are monitored in patients receiving stimulant
medications, including long-acting formulations.
Cardiovascular events
Cardiovascular safety concerns with psychostimulant
ADHD medications were raised based on rare occurrences
of sudden death and other cardiac events (Vetter et al.
2008). Psychostimulants modulate cardiovascular contrac-
tility and heart rate via sympathomimetic effects (Wilens
et al. 2006b), and changes in vital signs have been noted
with MPH and AMP treatments, including increases in
systolic and diastolic blood pressure (*2–6 mmHg) and
heart rate (*8 beats per minute) (Wilens et al. 2005). In
clinical trials of psychostimulants in children and adults, no
clinically significant changes in atrial or ventricular con-
duction or repolarization have been observed (Wilens et al.
2006b). An elevated risk of cardiac-related emergency
visits with current psychostimulant use versus non-use has
been reported (Winterstein et al. 2007; Winterstein et al.
2009), but in the majority of healthy children with no
history of or current cardiovascular abnormalities, psy-
chostimulants produced cardiovascular effects of minimal
clinical significance (Findling et al. 2001, 2005; Safer
1992; Wilens et al. 2006b). Similarly, a large, retrospec-
tive, population-based cohort study concluded that ADHD
medication use in children and young and middle-aged
adults was not associated with an increased risk of serious
cardiovascular events compared with non-use (Cooper
et al. 2011; Habel et al. 2011). However, when treatment
with any psychostimulant formulation is contemplated in a
patient with structural heart disease, or in a patient who has
a personal or a family history of syncope or sudden death,
respectively, a pediatric or cardiologic consultation prior to
ADHD pharmacological treatment is strongly advised
(Graham et al. 2011).
Abuse, misuse, and diversion
Prescription stimulants are classified as controlled sub-
stances, and their abuse, misuse, and diversion are impor-
tant public health and safety concerns (Kollins 2008;
Wilens et al. 2008). Since euphoria and drug ‘‘liking’’ are
linked to a more rapid rate of absorption and delivery to the
brain (Volkow and Swanson 2003), it follows that con-
trolling the rate of stimulant release may modify its
potential for abuse. Support for a lower abuse potential for
long-acting compared with short-acting stimulants includes
greater subjective responses for immediate-release stimu-
lants than OROS-MPH in healthy adults (Parasrampuria
et al. 2007; Spencer et al. 2006a). The formulation of
stimulants as once-daily medications also reduces the
likelihood of diversion by removing the requirement for
drug administration at school.
Many long-acting stimulants can be manipulated to
facilitate more rapid absorption of the active ingredient, for
example by crushing or dissolving the medications in order
to facilitate intranasal or parenteral administration (Mao
et al. 2011). However, the physical characteristics of
stimulant formulations, such as the non-deformable shell of
the OROS-MPH capsule, may make them more difficult to
break, cut, or crush. The prodrug design of LDX means that
the rate of active d-AMP release is limited by the rate of
enzymatic conversion, regardless of the route of drug
administration or capsule intactness. Thus, the plasma
concentration–time profile of intranasal LDX in healthy
men is similar to that following oral administration (Ermer
et al. 2011). In individuals with a history of stimulant
abuse, scores in the Drug Rating Questionnaire-Subject
liking scale for oral LDX (B100 mg) were no different to
placebo, whereas the equivalent oral dose of d-AMP
(40 mg) was favored over placebo (Jasinski and Krishnan
2009a). Similarly, unlike intravenous d-AMP 20 mg, an
equivalent intravenous dose of LDX (50 mg) did not pro-
duce subjective abuse-related liking scores (Jasinski and
Krishnan 2009a, b).
Adherence
Non-adherence to medication for chronic illnesses is esti-
mated to be approximately 50 % (World Health
260 F. A. Lo´pez, J. R. Leroux
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Organization 2003). In ADHD, the prevalence of medica-
tion discontinuation or non-adherence is reported to range
from 13 to 64 % (Adler and Nierenberg 2010). After
14 months of treatment with MPH in the MTA study,
analysis of saliva samples indicated that only 53.5 % of
patients were adherent at every assay point and that almost
25 % of patients were non-adherent at 50 % or more of
their assays (Pappadopulos et al. 2009). Studies that have
examined the impact of formulation on adherence and
persistence of stimulant medications for ADHD include
several retrospective claims analyses (Christensen et al.
2010; Marcus et al. 2005; Sanchez et al. 2005). The largest
of these identified over 60,000 newly treated patients with
ADHD (Christensen et al. 2010). This analysis indicated
that the mean (SD) adherence (defined as the ratio of the
number of days therapy supplied to the total number of
days persistent) to long-acting stimulants (0.56 [0.32]) was
significantly greater (p \ 0.0001) than that for short- (0.43
[0.35]) and intermediate-acting (0.47 [0.35]) stimulants.
Similarly, the mean (SD) persistence (defined as the
number of days out of 365 days plus the index day that the
patient remained on their index therapy) on long-acting
stimulants (239.5 [145.8]) was significantly greater
(p \ 0.0001) than for short- (186.7 [154.8]) or intermedi-
ate-acting (185.6 [153.4]) stimulants (Christensen et al.
2010). Furthermore, a chart review of Spanish adults with
ADHD found that the switch from short-acting MPH to
long-acting MPH was associated with a significant
improvement in all items of the Simplified Medication
Adherence Questionnaire (Ramos-Quiroga et al. 2008).
These data suggest that the choice of formulation has
important consequences on the adherence and persistence
of ADHD stimulant medications.
Treatment individualization
Evidence-based ADHD guidelines recognize that medica-
tion strategies should be tailored for the individual. Among
the factors to consider when selecting an appropriate
medication for a patient with ADHD are drug class and the
formulation required to give the desired pharmacokinetic
and pharmacodynamic profiles. The choice of medications
for ADHD includes both stimulants and non-stimulants.
With regard to stimulants, although mean responses to
MPH and AMP are similar, individuals may respond dif-
ferently to the two drugs. As reviewed by Arnold (2000),
approximately 28 % will respond preferentially to AMP,
17 % will respond preferentially to MPH, and less than
13 % will not respond to either (Arnold 2000). Where
stimulant medications are indicated, the selection of for-
mulation should be based both on clinical requirements and
on the preferences of the patient and/or their family. Short-
and long-acting formulations provide treatment options
ranging from approximately 4 h to, in the case of LDX,
more than 13 h in children (Wigal et al. 2009) and more
than 14 h in adults (Wigal et al. 2010). It is important to
note that suboptimal response to one class or formulation
of stimulant does not predict failure of another. Thus, a
recent post hoc analysis found that the clinical effective-
ness and rates of remission in children with ADHD who
were treated with LDX were similar in patients with a
previous suboptimal response to MPH treatment to those of
the overall study population (Jain et al. 2011).
Conclusions
The development of controlled-release formulations of
stimulants and the stimulant prodrug LDX has greatly
increased the number of pharmacological treatment options
for patients with ADHD. At equivalent systemic exposures,
the efficacy and safety of long-acting stimulants appear to
be equivalent to short-acting formulations. However, long-
acting medications offer several potential benefits to
patients. Long-acting stimulants offer efficacy for at least
13–14 h without augmentation. The convenience of once-
daily dosing may contribute to improved adherence of
long-acting stimulants compared with short-acting stimu-
lants. Prodrug technology may also provide lower inter-
and intra-patient variability in exposure than mechanical
controlled-release systems. Furthermore, long-acting stim-
ulants may be less prone to abuse than their short-acting
counterparts. Thus, the development of long-acting for-
mulations of stimulants provides important additional
treatment options for the management of ADHD.
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